Asian Energy Services Limited has initiated a significant global expansion move by acquiring 100% equity in Kuiper Holdings Limited and Kuiper Group Limited for $9.25 million. This acquisition was executed through its wholly owned subsidiary, Asian Oilfield & Energy Services DMCC (Dubai), positioning the company to strengthen its service portfolio across international markets.

Acquisition Details

The acquisition agreement was signed on 18th April 2025 with Offshore Logistics Services Holdings Limited, registered in the Cayman Islands. Upon completion, the Kuiper Group entities will become wholly owned subsidiaries of Asian DMCC and step-down subsidiaries of Asian Energy. 

Kuiper Group, with a reported turnover of $68 million in 2024, operates in the manpower solutions segment for the global energy industry. The acquisition, valued at $9.25 million in cash, awaits regulatory approval from the General Authority for Competition in Saudi Arabia and is expected to close within two to three months.

Expansion of Operational Capabilities

This acquisition is aligned with Asian Energy’s long-term strategy to expand its integrated operations and maintenance offerings across the Middle East and Southeast Asia. The Kuiper Group’s established presence in key global energy hubs and its track record with major projects make it a strategic addition to the company’s portfolio. 

There is no related party involvement, and the transaction has been executed at arm’s length, ensuring full regulatory compliance.

Read More: Asian Energy Services To Strengthen Financial Stability: ₹160 Crore Preferential Issue

Asian Energy Services Share Performance 

As of April 21, 2025, 10:30 AM, Asian Energy Services share price is trading at ₹316.35, reflecting a 1.42% drop from the previous closing price. Over the past month, the stock has surged by 11.65%.

Conclusion

The acquisition of the Kuiper Group marks a significant milestone in Asian Energy’s journey towards becoming a global player in the energy services industry. By leveraging Kuiper’s strengths, the company is set to broaden its reach and operational excellence across international markets.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

 

PSP Projects Limited has received a significant civil construction contract, marking another addition to its expanding project portfolio. The newly awarded project reflects the company’s continued momentum in the institutional infrastructure space within India.

Work Order for BIFC-2 Building in GIFT City

The company has been awarded a work order by Brigade (Gujarat) Projects Private Limited for civil structure and finishing work on the BIFC-2 Building, located at GIFT City in Gandhinagar, Gujarat. The contract, valued at ₹107.10 crore (excluding GST), falls under the institutional category and is expected to be executed within 24 months.

This new development underlines PSP Projects’ growing footprint in Gujarat’s premium business and financial hub, reinforcing its role in smart urban infrastructure projects.

Full Regulatory Compliance and No Related Party Involvement

PSP Projects has formally confirmed that this order does not fall under related party transactions. Neither the promoters nor any entities from the promoter group hold an interest in the awarding company.

Additionally, the company stated that all work orders, including this one, are secured from domestic entities, ensuring compliance with SEBI’s disclosure norms and reinforcing corporate transparency.

Read More: Adani Infra Gets CCI Approval for PSP Projects Stake Purchase

PSP Projects Share Performance 

As of April 21, 2025, 9:30 AM, PSP Projects Share Price is trading at ₹636.65, reflecting a 0.07% surge from the previous closing price. Over the past month, the stock has surged by 0.49%.

Conclusion

By acquiring this major institutional project, PSP Projects continues to consolidate its presence in strategic infrastructure zones. The contract serves as both a testament to its execution capability and a step forward in India’s infrastructure growth story.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Mahanagar Telephone Nigam Ltd (MTNL) is now grappling with a severe financial crisis. The company has defaulted on substantial loan repayments to multiple public sector banks, raising concerns over its long-term viability.

Over 8,300 Crore Default Across Multiple Lenders

MTNL has defaulted on loans totalling ₹8,346 crore, as per an exchange filing released on Saturday. The default includes principal and interest. The affected banks include Union Bank of India, Bank of India, Punjab National Bank, State Bank of India, UCO Bank, Punjab and Sind Bank, and Indian Overseas Bank.

These missed payments occurred in March and mark one of the largest defaults by a state-owned telecom firm in recent times. The company’s inability to service its debt has put further pressure on its financial standing.

Persistent Struggles of a Declining Telecom PSU

MTNL’s financial health has been deteriorating for several years due to mounting debt, declining revenues, and intense market competition. The latest defaults reflect the broader challenges faced by legacy telecom firms in adapting to a rapidly evolving industry.

Despite previous government bailouts and merger talks with BSNL, the company continues to face operational and financial hurdles, with limited visibility of a sustainable turnaround in sight.

Read More: BSNL, MTNL Earn ₹12,984 Crore From Monetisation; No Privatisation Planned

MTNL Share Performance 

As of April 21, 2025, 9:30 AM, MTNL Share Price is trading at ₹43.00, reflecting a 1.83% drop from the previous closing price. Over the past month, the stock has declined by 6.42%.

Conclusion

MTNL’s recent loan default underscores the depth of its financial distress and casts doubt on its revival prospects. With public sector banks already under pressure, the ripple effect of such defaults could pose additional challenges for the broader banking ecosystem.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

JB Chemicals & Pharmaceuticals Ltd. has received approval from the United States Food and Drug Administration (USFDA) to manufacture and market Bisoprolol Tablets USP in 5 mg and 10 mg strengths. The approval was issued under the Abbreviated New Drug Application (ANDA) route.

As of 9:20 am on April 21, 2025, J B Chemicals and Pharmaceuticals share price was trading at ₹1,654.50, a 0.50% up, down 13.59% over the past six months and 7.88% over the past year.

Generic Version of Zebeta

The product is a generic version of Teva’s Zebeta tablets, which are prescribed for the management of hypertension. Bisoprolol is used to treat high blood pressure and belongs to the beta-blocker class of medications.

Product Details

• Drug name: Bisoprolol Tablets USP
• Strengths approved: 5 mg and 10 mg
• Indication: Management of hypertension
• Brand reference: Zebeta (Teva)

Approval Route

The approval comes through the ANDA process, which allows pharmaceutical companies to market a generic version of a previously approved drug, provided it meets regulatory requirements for safety, efficacy, and bioequivalence.

In a regulatory filing dated April 18, 2025, the company informed the National Stock Exchange of India that it had secured the approval. The announcement was signed by Sandeep Phadnis, Vice President – Secretarial and Company Secretary, JB Chemicals.

Geographic Market

The approval allows JB Chemicals to introduce the product in the United States, one of the largest pharmaceutical markets globally. The company did not provide additional commercial or launch-related details in the announcement.

Read More: KKR Expected to Sell Stake in JB Chemicals: Check Key Details Here

Conclusion

With this USFDA approval, JB Chemicals is cleared to supply Bisoprolol tablets in the US market. The drug will serve as an alternative to the branded version for the treatment of hypertension. No further information regarding timelines or sales projections was disclosed in the filing.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

National Fertilizers Limited (NFL) will invest around ₹572.45 crore to acquire an 18% equity stake in a proposed joint venture company that will set up a new ammonia-urea plant in Namrup, Assam. The company’s board approved the proposal at its meeting held on April 18, 2025.

As of 9:20 AM on April 21, 2025, National Fertilizers share price was trading at ₹85.68, a 0.35% up, down 25.69% over the past six months and 16.63% over the past year.

Project Background

The joint venture aims to establish the Namrup-IV Fertilizer Plant within the existing premises of Brahmaputra Valley Fertilizer Corporation Ltd (BVFCL). The plant will have an annual urea production capacity of 12.7 lakh tonnes. It is being developed as a brownfield project.

Ownership Structure

The proposed shareholding in the joint venture is as follows:

• Government of Assam – 40%
• National Fertilizers Ltd – 18%
• Oil India Ltd – 18%
• Hindustan Urvarak & Rasayan Ltd – 13%
• Brahmaputra Valley Fertilizer Corporation Ltd – 11%

BVFCL’s contribution will be in the form of tangible assets instead of cash.

Project Cost and Other Details 

The estimated total project cost is ₹10,601.40 crore. The funding structure will follow a 70:30 debt-equity ratio. NFL’s share of ₹572.45 crore will be a cash investment.

The tentative timeline for mechanical completion and commissioning of the plant is 48 months from the project’s start date. The joint venture company is yet to be formally incorporated. Once operational, the plant is expected to cater to urea demand in Assam, Bihar, West Bengal, Eastern Uttar Pradesh, and Jharkhand.

Read More: Best Fertilizer Stocks in India in April 2025 – 5Y CAGR Basis

Regulatory Approvals

The Union Cabinet approved the project in March 2025. It falls under the administrative control of the Department of Fertilizers, Ministry of Chemicals and Fertilizers.

Conclusion

The Namrup-IV project is in the early stages of formation. NFL’s board has approved its participation alongside other public sector and state government entities. The joint venture will proceed with incorporation and project execution over the next four years.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Zydus Medtech, a subsidiary of Zydus Lifesciences, has signed a global licensing agreement with Brazil-based Braile Biomedica to commercialise its Transcatheter Aortic Valve Implantation (TAVI) system. The deal covers markets in India, Europe, and other selected regions.

As of 9:24 am on April 21, 2025, Zydus Lifesciences share price was trading at ₹831.75, a 0.024% up, down 17.38% over the past six months and 13.42% over the past year.

Rights and Responsibilities

Under the agreement, Zydus Medtech will hold exclusive rights to market Braile Biomedica’s balloon-expandable TAVI system in the mentioned geographies. Braile will continue manufacturing the device in Brazil, while Zydus will manage marketing and regulatory operations. In some cases, Zydus will also produce specific components of the system.

Market Context

The global market for TAVI devices is currently valued at over USD 6 billion. Demand has grown steadily due to the increasing preference for less invasive cardiac procedures. The partnership allows Zydus Medtech to enter the structural heart therapy space, where the company is actively building its interventional cardiology portfolio.

Plans

A clinical research programme for the TAVI device is expected to start next year. In addition to the current system, the agreement includes plans for a pipeline of new products to be launched over the next three years.

Overview

Zydus Lifesciences employs more than 27,000 people worldwide, including over 1,400 researchers. Braile Biomedica has nearly five decades of experience in cardiovascular device development and operates across Latin America.

The TAVI system is a medical device used in minimally invasive procedures to treat aortic stenosis. It is particularly used for elderly patients or those considered high-risk for open-heart surgery. The system uses a valve constructed from a single sheet of bovine pericardium, which differs from the standard three-leaflet structure. This design was initially developed as part of a doctoral thesis by cardiac surgeon Dr. Domingo Braile.

Read More: Why Did Lupin and Zydus Share Price Decline Sharply?

Conclusion

The licensing deal enables Zydus Medtech to expand its offerings in the cardiovascular space while supporting the global distribution of Braile’s TAVI technology.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Eternal Limited (formerly Zomato Limited) has proposed a cap of up to 49.5% on total foreign ownership. The board approved this on April 18, 2025. Shareholders will vote on the resolution through electronic postal ballot from April 20 to May 19, 2025. The outcome will be announced by May 21.

As of 9:32  am on April 21, 2025,  Eternal share price was trading at ₹227.96, a 1.58% down. The shares are down 19.25% over the past six months and up 10.96% over the past year.

What the Cap Covers

The proposed ceiling applies to all foreign investments, including:

• Foreign Direct Investment (FDI)
• Foreign Portfolio Investment (FPI)
• Indirect investments by NRIs
• Investments by foreign-owned or controlled Indian entities

This limit includes all equity instruments as defined under FEMA – equity shares, compulsorily convertible preference shares, and debentures, whether acquired in the primary or secondary market. The only exclusion is investments through the non-repatriation route.

Reason for the Cap

As of March 31, 2025, around 55% of Eternal’s fully diluted shareholding was held domestically, with foreign ownership at approximately 45%. This qualifies the company as an Indian-Owned and Controlled Company (IOCC) under Indian foreign exchange regulations. Eternal does not have a promoter group, so this cap is being proposed to maintain IOCC status.

Quick Commerce Link

Eternal’s quick commerce unit, Blinkit, is currently structured as a third-party marketplace. With IOCC classification in place, the company plans to gradually shift to owning inventory directly. Blinkit saw 93% YoY growth in gross order value (GOV) in FY24, and 123% growth over the nine-month period ending December 2024.

Read More: Zomato to Trade as ‘Eternal’ on Stock Exchanges Starting April 9, 2025

Conclusion

If shareholders approve the proposal, the cap will be implemented in compliance with FEMA and SEBI regulations. Any change in the company’s future classification may lead to a review of this limit.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.